Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.
暂无分享,去创建一个
L. Collette | S. Fosså | N. Aaronson | S. Horenblas | M. Brausi | J. Hetherington | P. Slee | R. Hall | L. D. Prijck | de Prijck L | S. D. Fosså | S. Fosså
[1] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Kantoff,et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Wessely,et al. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial , 1999, The Lancet.
[4] P. Kantoff,et al. Management of hormone refractory prostate cancer: current standards and future prospects. , 1998, The Journal of urology.
[5] P. Schellhammer,et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. , 1997, Urology.
[6] I. Christensen,et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. , 1997, The Journal of urology.
[7] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. R. Cooper,et al. Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables , 1995, Cancer.
[9] G. Bubley,et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.
[10] R. Sylvester,et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. , 1993, Urology.
[11] M Mazumdar,et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[13] H. Scher,et al. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. , 1993, The Journal of urology.
[14] S. Fosså,et al. Comparison of the effects of high dose estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: An interim analysis of EORTC-GU group study no. 30865 , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[15] P. Robinson,et al. Some Limitations of the Radioisotope Bone Scan in Patients With Metastatic Prostatic Cancer , 1990, Cancer.
[16] P. Goodman,et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.
[17] I. Tannock,et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Kirschner,et al. Medical Adrenalectomy for Advanced Prostatic Cancer: Clinical and Hormonal Effects , 1988, American journal of clinical oncology.
[19] R. Priore,et al. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer. , 1988, Urology.
[20] F. Labrie,et al. Benefits of combination therapy with flutamide in patients relapsing after castration. , 1988, British journal of urology.
[21] A. Coates,et al. Aminoglutethimide in advanced prostatic carcinoma. , 1987, British journal of urology.
[22] T. Chard,et al. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. , 1987, British journal of urology.
[23] P. Schellhammer,et al. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. , 1996, Urology.
[24] L. Boccon‐Gibod. Nonsteroidal antiandrogen monotherapy of metastatic cancer of the prostate. , 1993, European urology.
[25] S. Fosså,et al. Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. , 1989, European urology.
[26] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.